Autres langues Sage Therapeutics, Inc.

Actions

SAGE

US78667J1088

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 06/05/2024			Varia. 5j.	Varia. 1 janv.
13,25 ^USD	-4,95 %		-6,56 %	-38,86 %

26/04	SAGE THERAPEUTICS, INC. : Truist Securities est neutre	ZM
25/04	Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE	00:38
Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE	28/04
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M	25/04
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	25/04
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Sage Therapeutics, Inc. Announces Not Standing for Re-Election of Board of Directors	24/04
Sage Therapeutics, Inc. Announces Not Standing for Re-Election of Board of Directors	24/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease	18/04
Top Midday Decliners	17/04
Sector Update: Health Care Stocks Advance Premarket Wednesday	17/04
Sector Update: Health Care	17/04
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17/04
Top Premarket Decliners	17/04
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	17/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	17/04
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17/04
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	11/04
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors	26/03
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26/03
Sage Therapeutics to Present at Upcoming March Investor Conferences	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sage Therapeutics, Inc.

Actions

SAGE

US78667J1088

Autres langues

Filtres